Tim Herbert has run Inspire, whose neurostimulation technology is designed to treat obstructive sleep apnea, ever since it was spun off from Medtronic in 2007. He’s been nothing if not dogged: It took till 2014 for the treatment to earn FDA approval. In 2018, Herbert oversaw an IPO (NYSE: INSP). The share price had climbed 50 percent as of September, suggesting that the market sees promise in the technology’s acceptance. Revenue has risen from $8 million in 2015 to more than $50 million in 2018. That noted, Inspire also posted a net loss last year of nearly $22 million. A bright spot going forward: In July, insurer UnitedHealthcare announced it would cover Inspire’s therapy.